N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
Phase 2 N=94 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Basal Cell Carcinoma · Skin Cancer · Cancer of the Skin, Basal Cell
Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants
Phase 2 N=29 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Basal Cell Carcinoma (BCC) · Skin Cancer
Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04
Early Phase 1 N=15 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated — -26.8 percentage size change from baseline
Phase 2 N=186 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 3 N=169 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC) — 119 participants
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Phase 1 N=28 Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Clinical Response to Photodynamic Therapy — 9; 14; 5 lesions
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
Phase 2 N=74 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463
Phase 2 N=230 A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell…
Phase 2 N=5 Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 2 N=41 To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
Basal Cell Nevus Syndrome · Gorlin Syndrome
Primary: Number of New Surgically Eligible Basal-cell Carcinomas — 34; 2 events per patient year
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm
Phase 1 N=21 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
Carcinoma, Basal Cell (BCC)
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 1; 12 participants
N/A N=12 Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
Nodular Basal Cell Carcinoma · Superficial Basal Cell Carcinoma
Primary: Percentage of Lesions Cleared Histologically — 3; 5 Lesion
Phase 2 N=30 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate — 69.7 percentage of tumor lesions
Phase 2 N=36 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Neoplastic Syndrome
Primary: Complete Response Rate — 2 Participants
Phase 2 N=36 Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
Basal Cell Carcinomas
Primary: Number of Treatment-emergent Adverse Events (Including Both Serious and Non-Serious) Causally Related to Study Drug — 0; 0; 0; 2 number of events
Phase 2 N=28 Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Basal Cell Carcinoma
Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors
N/A N=11 Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Basal Cell Carcinoma
Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks
Phase 1 N=25 Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
Carcinoma, Basal Cell
Primary: Determination of RP2D — 1000 mg
Phase 3 N=174 Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Basal Cell Nevus Syndrome
Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas
N/A N=23 Pilot Study of PDL to Treat BCC and SCCIS
Basal Cell Carcinoma · Squamous Cell Carcinoma in Situ
Primary: Tumor Clearance — 2; 2; 5 Participants
Phase 2 N=1,215 STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse…
Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants